Lisa Keiner
Internal Medicine · Philadelphia, PANPI 1497865497
Payments from drug & device makers
Across 85 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$240
- AstraZeneca$226
- Novo Nordisk$224
- Daiichi Sankyo Inc.$163
- AbbVie$121
- Astellas Pharma US Inc$107
- plus $538 from 13 others
What the payments were for
- Food & beverage$1,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $240 |
| AstraZeneca | 14 | $226 |
| Novo Nordisk | 14 | $224 |
| Daiichi Sankyo Inc. | 3 | $163 |
| AbbVie(2 entities) | 3 | $121 |
| Astellas Pharma US Inc | 6 | $107 |
| Boehringer Ingelheim | 5 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| GSK | 4 | $60 |
| Boston Scientific | 2 | $53 |
| Johnson & Johnson | 4 | $51 |
| Amgen | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $36 |
| Bausch Health US, LLC | 2 | $28 |
| Merck | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Nevro Corp. | 1 | $19 |
| Pfizer | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$123
How this compares
$1,619 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $39,564 |
| JardianceEmpagliflozin | 14 | $21,057 |
| XareltoRivaroxaban | 11 | $16,505 |
| JanuviaSitagliptin Phosphate | 11 | $12,926 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $5,513 |
| CymbaltaDuloxetine Hcl | 16 | $4,173 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,382 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,937 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,696 |
| Atorvastatin Calcium | 159 | $1,633 |
| Duloxetine Hcl | 30 | $1,138 |
| Gabapentin | 58 | $1,009 |
| Rosuvastatin Calcium | 43 | $794 |
| Metoprolol Succinate | 40 | $660 |
| Levothyroxine Sodium | 37 | $634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $39,56434 claims |
| Boehringer IngelheimJardiance | $105 | $21,05714 claims |
| Johnson & JohnsonXarelto | $51 | $16,50511 claims |
| MerckJanuvia | $28 | $12,92611 claims |
| Lilly USA, LLCCymbalta | $240 | $4,17316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Walter KraftPhiladelphia$3.7M
- Daniel RaderPhiladelphia$3.3M
- Archna BajajPhiladelphia$2.9M
- Gary YeomanPhiladelphia$2.4M
- Melina MarmarelisPhiladelphia$2.1M
- Adam WaxmanPhiladelphia$894K
- Donna GavaronePhiladelphia$728K
- Eyob FeyssaPhiladelphia$693K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.